Your browser is no longer supported. Please, upgrade your browser.
Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own0.67% Shs Outstand6.95M Perf Week-3.27%
Market Cap37.74M Forward P/E- EPS next Y-1.97 Insider Trans0.00% Shs Float6.90M Perf Month-9.51%
Income-10.90M PEG- EPS next Q-0.49 Inst Own6.90% Short Float3.29% Perf Quarter-40.31%
Sales- P/S- EPS this Y12.60% Inst Trans-2.20% Short Ratio0.27 Perf Half Y57.69%
Book/sh3.49 P/B1.53 EPS next Y0.50% ROA-63.40% Target Price- Perf Year6.18%
Cash/sh1.95 P/C2.73 EPS next 5Y- ROE-70.00% 52W Range3.12 - 24.34 Perf YTD52.29%
Dividend- P/FCF- EPS past 5Y25.30% ROI- 52W High-78.10% Beta1.94
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin- 52W Low70.83% ATR0.40
Employees10 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)38.80 Volatility6.97% 6.78%
OptionableNo Debt/Eq0.00 EPS Q/Q20.40% Profit Margin- Rel Volume0.15 Prev Close5.13
ShortableYes LT Debt/Eq0.00 EarningsMay 14 BMO Payout- Avg Volume853.25K Price5.33
Recom2.00 SMA20-7.69% SMA50-17.14% SMA2008.07% Volume125,367 Change3.90%
Mar-11-21Initiated ROTH Capital Buy $13
Nov-13-17Reiterated H.C. Wainwright Buy $4.50 → $1.50
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
May-14-21 07:00AM  
May-07-21 07:00AM  
Apr-26-21 09:00AM  
Apr-22-21 07:00AM  
Apr-12-21 07:00AM  
Apr-05-21 08:03AM  
Mar-11-21 07:00AM  
Mar-10-21 07:00AM  
Mar-03-21 04:01PM  
Feb-18-21 04:01PM  
Feb-16-21 07:15AM  
Feb-13-21 07:00AM  
Feb-10-21 07:08AM  
Dec-21-20 02:05PM  
Dec-11-20 03:48AM  
Nov-19-20 07:00AM  
Nov-13-20 07:00AM  
Nov-06-20 08:00AM  
Oct-22-20 07:00AM  
Sep-18-20 12:00PM  
Sep-09-20 08:00AM  
Aug-14-20 07:00AM  
Aug-13-20 07:00AM  
Aug-07-20 08:00AM  
Jun-25-20 11:28PM  
Jun-17-20 07:30AM  
May-29-20 08:00AM  
May-15-20 07:00AM  
May-13-20 05:00PM  
May-08-20 08:00AM  
Apr-27-20 09:00AM  
Apr-13-20 07:00AM  
Mar-13-20 07:39PM  
Mar-11-20 07:00AM  
Mar-06-20 07:00AM  
Feb-28-20 08:00AM  
Feb-21-20 10:34AM  
Jan-23-20 09:07AM  
Jan-08-20 08:00AM  
Dec-06-19 09:25AM  
Dec-05-19 09:42PM  
Dec-04-19 12:00PM  
Nov-26-19 08:00AM  
Nov-25-19 02:11PM  
Nov-21-19 11:30AM  
Nov-15-19 07:00AM  
Nov-08-19 08:00AM  
Oct-29-19 06:47AM  
Oct-16-19 02:29PM  
Oct-15-19 08:00AM  
Sep-25-19 08:00AM  
Sep-14-19 09:36AM  
Sep-04-19 01:10AM  
Sep-03-19 04:01PM  
Aug-26-19 07:00AM  
Aug-15-19 07:00AM  
Aug-08-19 04:01PM  
Jul-17-19 11:39AM  
Jul-16-19 08:18AM  
Jun-04-19 11:51AM  
May-16-19 07:05AM  
May-15-19 08:16AM  
May-10-19 04:01PM  
Apr-29-19 09:00AM  
Apr-15-19 04:33PM  
Apr-03-19 08:00AM  
Mar-21-19 06:13AM  
Mar-20-19 09:15AM  
Mar-15-19 04:01PM  
Mar-14-19 03:10PM  
Mar-12-19 09:15AM  
Mar-08-19 01:25PM  
Mar-07-19 11:55AM  
Mar-06-19 02:35PM  
Mar-04-19 06:10AM  
Feb-28-19 08:00AM  
Jan-24-19 04:30PM  
Jan-23-19 04:01PM  
Jan-18-19 12:31PM  
Jan-17-19 04:07PM  
Jan-16-19 08:24AM  
Jan-14-19 10:23PM  
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.